Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of pembrolizumab when given
together with chemoradiotherapy or radiation therapy in treating patients with small cell
lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the
body's immune system attack the cancer, and may interfere with the ability of tumor cells to
grow and spread. Radiation therapy uses high energy x-rays to kill cancer cells and shrink
tumors. Giving chemotherapy with radiation therapy may kill more cancer cells. Giving
pembrolizumab with chemoradiotherapy or radiation therapy may be a better treatment for small
cell lung cancer.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Merck Sharp & Dohme Corp. National Cancer Institute (NCI)